Skip to main content
EYPT logo

EyePoint Pharmaceuticals, Inc. (EYPT) Stock: Price, Forecast & Analyst Target

EyePoint Pharmaceuticals, Inc. (EYPT) — MoonshotScore 18/100 (Weak band), calculated Nov 18, 2026. Price $0.2642 (-2.87%), as of the Nov 19, 2026 trading session; market cap $30.1M.

Educational signal · not a buy or sell recommendation · How to read this

$0.2642 −$0.0078 (-2.87%) Market Cap $30.1M

EyePoint Pharmaceuticals, Inc. · EYPT · NASDAQ

EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing ophthalmic products for treating eye diseases. The company's portfolio includes treatments for diabetic macular edema, uveitis, and post-operative ocular inflammation, with a pipeline focused on sustained-release technologies.

Price as of Nov 19, 2026

Key Statistics

18 of 100

MoonshotScore v2 · EyePoint Pharmaceuticals (EYPT)

Weak
Business Quality Poor (11)
Financial Safety Strained (22)
Valuation Fair (68)
Growth Durability Shrinking (3)
Momentum Falling (11)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet and stalling growth — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Fair; Growth Durability: Shrinking; Momentum: Falling.

  • quarterly revenue $756,000 (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 0 of the last 8 reports
  • Altman Z -17.32 · Piotroski F 2

Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for EYPT (57 recorded, newest six shown)
RecordedScoreBand
17Weak
17Weak
23Weak
23Weak
18Weak
18Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.2642
Change on the day-2.87%
52-week range$0.2642 – $19.11
Market capitalisation$30.1M—
Shares traded on the day3.44M

Price & events

Other perspectives

Council score for EyePoint Pharmaceuticals (EYPT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Moderate
Growth Durability Negative
Momentum Negative

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Moderate
ROE Negative
Gross Margin Moderate

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is EyePoint Pharmaceuticals (EYPT), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. EyePoint Pharmaceuticals, Inc. (EYPT) is listed on NASDAQ. It employs 214 people and is led by Jay S. Duker. In Q3 FY2026 it reported revenue of $756,000 and net income of -$96M. The market values it at $30.1M.

2 · Latest results

What do the latest results show for EyePoint Pharmaceuticals (EYPT)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $756,000. Against analyst estimates the company has EPS beat 0 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$756,000-$96M-$1.07 (diluted)
Q2 FY2026$507,000-$94M-$1.09 (diluted)
Q1 FY2026$696,000-$85M-$0.99 (diluted)
Q4 FY2025$620,000-$68M-$0.81 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for EyePoint Pharmaceuticals (EYPT)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -17.32 · Piotroski F 2. Trailing ratios: current ratio 3.30.

Data-derived red flags

  • Listing risk — at $0.2642 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -17.32 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
4 · What to check next?

What should you watch next at EyePoint Pharmaceuticals (EYPT)?

Short answer · as of

Current published price targets run low $0.50 · high $40.00 · consensus $11.21 · median $4.00 against a quoted price of $0.2642 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does EyePoint Pharmaceuticals compare with its peers?

Short answer

EyePoint Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026
EyePoint Pharmaceuticals (EYPT) — this page$0.2642$30.1M18

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$0.50 – $40.00
Consensus target
$11.21
Median target
$4.00

Consensus record · Captured .

Measured against a quoted price of $0.2642 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held EYPT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported EYPT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about EyePoint Pharmaceuticals (EYPT)?

Read these with our analysis →

Investor Questions: EYPT Stock

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for EYPT?

EYPT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing ophthalmic products for treating eye diseases.

Is EYPT a good stock to buy?

Stock Expert AI does not rate EYPT buy, sell or hold. EyePoint Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the EYPT stock price today?

The last price recorded for EyePoint Pharmaceuticals, Inc. (EYPT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the EYPT price target?

The analyst consensus price target for EyePoint Pharmaceuticals, Inc. (EYPT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the key factors to evaluate for EYPT?

EyePoint Pharmaceuticals, Inc. (EYPT) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Strategic collaborations with Alimera Sciences, Bausch & Lomb, and Ocumension Therapeutics expand market reach and product development capabilities. Not financial advice.

How frequently does EYPT data refresh on this page?

EYPT's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven EYPT's recent stock price performance?

EyePoint Pharmaceuticals, Inc. (EYPT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative sustained-release drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider EYPT overvalued or undervalued right now?

EyePoint Pharmaceuticals, Inc. (EYPT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of EYPT?

Fractional-share availability for EyePoint Pharmaceuticals, Inc. (EYPT) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.